FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) Files An 8-K Other EventsItem 8.01 Other Events.
On March 06, 2018, Fibrocell Science, Inc. (the "Company") issued a press release announcing the FDA allowance of investigational new drug application for FCX-013 for the treatment of moderate to severe localized scleroderma. A copy of the press release is attached hereto as Exhibit 99.1.
On March 06, 2018, Fibrocell Science Inc., posted an updated Corporate Presentation on its website www.fibrocell.com. A copy of the presentation is filed herewith as Exhibit 99.2 and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
Fibrocell Science, Inc. ExhibitEX-99.1 2 fcsc030518finalfcscfcx01.htm EXHIBIT 99.1 fcsc030518finalfcscfcx01
Fibrocell Announces FDA Allowance of Investigational New Drug Application for FCX-013
for the Treatment of Moderate to Severe Localized Scleroderma
EXTON,…To view the full exhibit click here
About FIBROCELL SCIENCE, INC. (NASDAQ:FCSC)
Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.